Compass Pathways PLC Sponsored ADR (CMPS) – What Are Brokerages Thinking About This Stock?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $23.36.

A number of research analysts recently commented on the company. Jefferies Financial Group reissued a “buy” rating on shares of Compass Pathways in a research note on Wednesday, September 9th. Wall Street Zen cut Compass Pathways from a “sell” rating to a “strong sell” rating in a report on Saturday. BTIG Research increased their price objective on Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Wells Fargo & Company began coverage on Compass Pathways in a report on Monday, July 27th. They set an “equal weight” rating and a $13.00 price objective on the stock. Finally, B. Riley Financial boosted their target price on Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th.

Compass Pathways Price Performance

Shares of NASDAQ:CMPS opened at $11.57 on Monday. The company’s fifty day moving average price is $12.91 and its 200-day moving average price is $10.38. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -2.50 and a beta of 2.43. Compass Pathways has a one year low of $4.88 and a one year high of $15.87. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). On average, equities research analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Integrity Alliance LLC. bought a new stake in Compass Pathways in the third quarter worth $128,000. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Compass Pathways by 23.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 399,506 shares of the company’s stock valued at $4,970,000 after buying an additional 76,297 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Compass Pathways during the third quarter valued at about $85,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Compass Pathways by 15.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,432 shares of the company’s stock valued at $317,000 after buying an additional 3,249 shares during the last quarter. Finally, North Star Investment Management Corp. increased its holdings in shares of Compass Pathways by 23.9% in the third quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock worth $116,000 after buying an additional 1,800 shares during the period. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.